Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAS-103 dihydrochloride (BMS-247615 dihydrochloride) 是可用于癌症研究的一种 DNA 拓扑异构酶 I/II 双重抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 398 | 现货 | ||
5 mg | ¥ 898 | 现货 | ||
10 mg | ¥ 1,360 | 现货 | ||
25 mg | ¥ 2,890 | 现货 | ||
50 mg | ¥ 4,320 | 现货 | ||
100 mg | ¥ 6,170 | 现货 |
产品描述 | TAS-103 dihydrochloride (BMS-247615 dihydrochloride) is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II. |
体外活性 | The in vitro antitumor effects of TAS-103 were compared with those of other known Topo I and Topo II inhibitors. TAS-103 inhibited DNA synthesis more strongly than RNA and protein synthesis, and induced an increase of cell population in the S-G2/M phase. The cytotoxicity of TAS-103 was strongest against S-phase cells, but its cell cycle phase specificity was not clear, and depended on drug concentration and exposure time. The cytotoxicity of TAS-103 (IC50: 0.0030-0.23 microM) against various tumor cell lines was much stronger than that of VP-16 and comparable to that of SN-38. The cytotoxicity of TAS-103 seemed to be more related to the amount of protein-DNA complexes than to the accumulation of TAS-103 in the cells. P-Glycoprotein (P-gp)-mediated MDR, CDDP-resistant and 5-FU-resistant cell lines did not show cross-resistance to TAS-103. Although PC-7/CPT cells bearing a Topo I gene mutation showed cross-resistance to TAS-103, the sensitivity of P388/CPT, HT-29/CPT and St-4/CPT cells, showing decreased Topo I expression, was not changed. KB/VM4 and HT-29/Etp cells, showing decreased Topo II expression, were slightly cross-resistant to TAS-103. These results suggest that TAS-103 may act as an inhibitor of both Topo I and Topo II at the cellular level[1]. |
别名 | 6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-C]喹啉-7-酮二盐酸盐, TAS-103 (dihydrochloride), BMS-247615 dihydrochloride |
分子量 | 406.31 |
分子式 | C20H21Cl2N3O2 |
CAS No. | 174634-09-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (123.06 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 2.4612 mL | 12.3059 mL | 24.6117 mL | 61.5294 mL |
5 mM | 0.4922 mL | 2.4612 mL | 4.9223 mL | 12.3059 mL | |
10 mM | 0.2461 mL | 1.2306 mL | 2.4612 mL | 6.1529 mL | |
20 mM | 0.1231 mL | 0.6153 mL | 1.2306 mL | 3.0765 mL | |
50 mM | 0.0492 mL | 0.2461 mL | 0.4922 mL | 1.2306 mL | |
100 mM | 0.0246 mL | 0.1231 mL | 0.2461 mL | 0.6153 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TAS-103 dihydrochloride 174634-09-4 DNA Damage/DNA Repair Topoisomerase TAS-103 TAS 103 6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-C]喹啉-7-酮二盐酸盐 inhibit TAS 103 dihydrochloride TAS-103 Dihydrochloride TAS-103 (dihydrochloride) Inhibitor TAS103 dihydrochloride BMS-247615 Dihydrochloride TAS103 Dihydrochloride TAS103 BMS-247615 BMS 247615 BMS-247615 dihydrochloride BMS 247615 Dihydrochloride TAS 103 Dihydrochloride BMS247615 BMS247615 Dihydrochloride inhibitor